Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

David B. Page; Harry Bear; Sangeetha Prabhakaran; Margaret E. Gatti-Mays; Alexandra Thomas; Erin Cobain; Heather McArthur; Justin M. Balko; Sofia R. Gameiro; Rita Nanda; James L. Gulley; Kevin Kalinsky; Julia White; Jennifer Litton; Steven J. Chmura; Mei Yin Polley; Benjamin Vincent; David W. Cescon; Mary L. Disis; Joseph A. Sparano; Elizabeth A. Mittendorf; Sylvia Adams

doi:10.1038/s41523-019-0130-x

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

David B. Page, Harry Bear, Sangeetha Prabhakaran, Margaret E. Gatti-Mays, Alexandra Thomas, Erin Cobain, Heather McArthur, Justin M. Balko, Sofia R. Gameiro, Rita Nanda, James L. Gulley, Kevin Kalinsky, Julia White, Jennifer Litton, Steven J. Chmura, Mei Yin Polley, Benjamin Vincent, David W. Cescon, Mary L. Disis, Joseph A. SparanoElizabeth A. Mittendorf, Sylvia Adams

Medicine

Research output: Contribution to journal › Review article › peer-review

56 Scopus citations

Abstract

Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.

Original language	English (US)
Article number	34
Journal	npj Breast Cancer
Volume	5
Issue number	1
DOIs	https://doi.org/10.1038/s41523-019-0130-x
State	Published - Dec 1 2019

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41523-019-0130-x

Cite this

Page, D. B., Bear, H., Prabhakaran, S., Gatti-Mays, M. E., Thomas, A., Cobain, E., McArthur, H., Balko, J. M., Gameiro, S. R., Nanda, R., Gulley, J. L., Kalinsky, K., White, J., Litton, J., Chmura, S. J., Polley, M. Y., Vincent, B., Cescon, D. W., Disis, M. L., ... Adams, S. (2019). Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. npj Breast Cancer, 5(1), Article 34. https://doi.org/10.1038/s41523-019-0130-x

Page, DB, Bear, H, Prabhakaran, S, Gatti-Mays, ME, Thomas, A, Cobain, E, McArthur, H, Balko, JM, Gameiro, SR, Nanda, R, Gulley, JL, Kalinsky, K, White, J, Litton, J, Chmura, SJ, Polley, MY, Vincent, B, Cescon, DW, Disis, ML, Sparano, JA, Mittendorf, EA & Adams, S 2019, 'Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer', npj Breast Cancer, vol. 5, no. 1, 34. https://doi.org/10.1038/s41523-019-0130-x

@article{a9083fc7eabf46a1a23fe9e183fd5f06,

title = "Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer",

abstract = "Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.",

author = "Page, {David B.} and Harry Bear and Sangeetha Prabhakaran and Gatti-Mays, {Margaret E.} and Alexandra Thomas and Erin Cobain and Heather McArthur and Balko, {Justin M.} and Gameiro, {Sofia R.} and Rita Nanda and Gulley, {James L.} and Kevin Kalinsky and Julia White and Jennifer Litton and Chmura, {Steven J.} and Polley, {Mei Yin} and Benjamin Vincent and Cescon, {David W.} and Disis, {Mary L.} and Sparano, {Joseph A.} and Mittendorf, {Elizabeth A.} and Sylvia Adams",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = dec,

day = "1",

doi = "10.1038/s41523-019-0130-x",

language = "English (US)",

volume = "5",

journal = "npj Breast Cancer",

issn = "2374-4677",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Two may be better than one

T2 - PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

AU - Page, David B.

AU - Bear, Harry

AU - Prabhakaran, Sangeetha

AU - Gatti-Mays, Margaret E.

AU - Thomas, Alexandra

AU - Cobain, Erin

AU - McArthur, Heather

AU - Balko, Justin M.

AU - Gameiro, Sofia R.

AU - Nanda, Rita

AU - Gulley, James L.

AU - Kalinsky, Kevin

AU - White, Julia

AU - Litton, Jennifer

AU - Chmura, Steven J.

AU - Polley, Mei Yin

AU - Vincent, Benjamin

AU - Cescon, David W.

AU - Disis, Mary L.

AU - Sparano, Joseph A.

AU - Mittendorf, Elizabeth A.

AU - Adams, Sylvia

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.

AB - Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.

UR - http://www.scopus.com/inward/record.url?scp=85073571292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073571292&partnerID=8YFLogxK

U2 - 10.1038/s41523-019-0130-x

DO - 10.1038/s41523-019-0130-x

M3 - Review article

AN - SCOPUS:85073571292

SN - 2374-4677

VL - 5

JO - npj Breast Cancer

JF - npj Breast Cancer

IS - 1

M1 - 34

ER -

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this